Literature DB >> 9707575

Morphine-activated opioid receptors elude desensitization by beta-arrestin.

J L Whistler1, M von Zastrow.   

Abstract

mu opioid receptors are targets of native opioid peptides and addictive analgesic drugs. A major clinical liability of opiate drugs is their ability to cause physiological tolerance. Individual opiates, such as morphine and etorphine, differ both in their ability to promote physiological tolerance and in their effects on receptor regulation by endocytosis. Here, we demonstrate that arrestins play a fundamental role in mediating this agonist-selective regulation and that morphine-activated mu receptors fail to undergo arrestin-dependent uncoupling from cognate G proteins. Thus, highly addictive opiate drugs elude a fundamental mode of physiological regulation that is mediated by agonist-specific interaction of opioid receptors with arrestins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707575      PMCID: PMC21436          DOI: 10.1073/pnas.95.17.9914

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

2.  beta-Arrestin: a protein that regulates beta-adrenergic receptor function.

Authors:  M J Lohse; J L Benovic; J Codina; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1990-06-22       Impact factor: 47.728

3.  Agonist-induced state of the delta-opioid receptor that discriminates between opioid peptides and opiate alkaloids.

Authors:  M Von Zastrow; D E Keith; C J Evans
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

4.  Visual arrestin binding to rhodopsin. Diverse functional roles of positively charged residues within the phosphorylation-recognition region of arrestin.

Authors:  V V Gurevich; J L Benovic
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

5.  Selectivity in the control of opiate receptor density in the animal and in cultured fetal brain cells.

Authors:  R Simantov; J Lotem; R Levy
Journal:  Neuropeptides       Date:  1984-12       Impact factor: 3.286

6.  Decrease in delta-opioid receptor density in rat brain after chronic [D-Ala2,D-Leu5]enkephalin treatment.

Authors:  P L Tao; L R Chang; P Y Law; H H Loh
Journal:  Brain Res       Date:  1988-10-18       Impact factor: 3.252

7.  Down-regulation of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. Chloroquine promotes accumulation of tritiated enkephalin in the lysosomes.

Authors:  P Y Law; D S Hom; H H Loh
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

8.  Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors.

Authors:  V V Gurevich; S B Dion; J J Onorato; J Ptasienski; C M Kim; R Sterne-Marr; M M Hosey; J L Benovic
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

9.  Effects of mutant rat dynamin on endocytosis.

Authors:  J S Herskovits; C C Burgess; R A Obar; R B Vallee
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

10.  Induction of mutant dynamin specifically blocks endocytic coated vesicle formation.

Authors:  H Damke; T Baba; D E Warnock; S L Schmid
Journal:  J Cell Biol       Date:  1994-11       Impact factor: 10.539

View more
  124 in total

1.  Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity.

Authors:  A Claing; S J Perry; M Achiriloaie; J K Walker; J P Albanesi; R J Lefkowitz; R T Premont
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Recycling and resensitization of delta opioid receptors.

Authors:  N Trapaidze; I Gomes; M Bansinath; L A Devi
Journal:  DNA Cell Biol       Date:  2000-04       Impact factor: 3.311

3.  Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells.

Authors:  L M Bohn; M M Belcheva; C J Coscia
Journal:  J Neurochem       Date:  2000-02       Impact factor: 5.372

Review 4.  G-protein coupled receptor kinases as modulators of G-protein signalling.

Authors:  M Bünemann; M M Hosey
Journal:  J Physiol       Date:  1999-05-15       Impact factor: 5.182

5.  Differential desensitization of responses mediated by presynaptic and postsynaptic A1 adenosine receptors.

Authors:  Jonathon P Wetherington; Nevin A Lambert
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

6.  Cholesterol regulates micro-opioid receptor-induced beta-arrestin 2 translocation to membrane lipid rafts.

Authors:  Yu Qiu; Yan Wang; Ping-Yee Law; Hong-Zhuan Chen; Horace H Loh
Journal:  Mol Pharmacol       Date:  2011-04-25       Impact factor: 4.436

7.  Chronic morphine treatment reduces recovery from opioid desensitization.

Authors:  Vu C Dang; John T Williams
Journal:  J Neurosci       Date:  2004-09-01       Impact factor: 6.167

Review 8.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Essential role for RGS9 in opiate action.

Authors:  Venetia Zachariou; Dan Georgescu; Nick Sanchez; Zia Rahman; Ralph DiLeone; Olivier Berton; Rachael L Neve; Laura J Sim-Selley; Dana E Selley; Stephen J Gold; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.